BioCentury
ARTICLE | Clinical News

AGN-214868: Phase II started

March 14, 2011 7:00 AM UTC

Syntaxin said Allergan began a double-blind, placebo-controlled, international Phase II trial to evaluate 3,250 and 16,250 ng AGN-214868 in about 280 patients. Syntaxin said the start of Phase II tria...